Geneuity (@Geneuity) header
Geneuity (@Geneuity) profile picture

Geneuity

@Geneuity

We improve medicine through innovative science. We integrate #genomics & #pathology to support #clinicaltrials, #companionDx & IVD #medicaldevice validation

 Maryville, TN
geneuity.com
Joined May 2015
  • Tweets452
  • Following231
  • Followers131
5Media
Photo by Geneuity (@Geneuity)Photo by Geneuity (@Geneuity)
Consolidation in the clinical research industry may disrupt the supply chains of top pharmaceutical companies. Working with mega-CROs has risk. blog.thesmartcube.com/mega-c…
Image from Geneuity (@Geneuity)
The Food and Drug Administration is endorsing a new approach that would rely on biomarkers to approve medicines before patients show any signs of the illness, instead of demonstrating a drug alleviates symptoms statnews.com/2018/03/05/alzh…
FDA's updated standards remove an unnecessary barrier to testing Alzheimer's drugs

FDA's updated standards remove an unnecessary barrier to testing Alzheimer's drugs

The FDA is finally modernizing its approach to evaluating new Alzheimer's drugs.

statnews.com
1
“A blood test to aid in concussion evaluation is an important tool for the American public and for our Service Members abroad who need access to quick and accurate tests,” said Jeffrey Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. nitter.gq/banyanbio/status/96386…
Banyan Biomarkers (@banyanbio) profile pictureBanyan Biomarkers@banyanbio14 Feb 2018
FDA Grants Marketing Authorization to Banyan Biomarkers for the First Diagnostic Blood Test for #TraumaticBrainInjury bit.ly/2sv3VMP #TBI #Concussion
Image from Banyan Biomarkers (@banyanbio)
Geneuity retweeted
MPLN (@molpathnet) profile picture
MPLN@molpathnet10 Jul 2017
Review @JCO_ASCO, Childhood Brain Tumors: Genome-Wide Discovery and Precision Medicine ascopubs.org/doi/pdf/10.1200…
1
1st Large-Scale Genomic Analysis T-Cell Acute Lymphoblastic #Leukemia Will Likely Yield New Therapies @TheBioConnect bit.ly/2uizWEB
1
Emerging Concepts in the Management of Central Nervous System Malignancies including #glioma @JCO_ASCO bit.ly/2s2V0gU
Geneuity retweeted
MPLN (@molpathnet) profile picture
MPLN@molpathnet26 Jun 2017
B.Tandon MD. presents workshop: Contemporary Genomic studies in hematologic #pathology: #nextgenerationsequencing bit.ly/2s3CaW4
1
Geneuity retweeted
MPLN (@molpathnet) profile picture
MPLN@molpathnet26 Jun 2017
Dr. Bevan Tandon presents workshop: 13th Int.Conference on Pathology and Molecular Diagnosis June 27th in San Diego bit.ly/2symIVj
1
Retrospective data from #Keytruda trial #HeadandNeckCancer. PD-L2 and PD-L1 expression associated w/ higher response & longer survival rate nitter.gq/GenomeWeb/status/87753…
GenomeWeb (@GenomeWeb) profile pictureGenomeWeb@GenomeWeb21 Jun 2017
New #immunotherapy marker PD-L2 may be a better predictor of response to PD-1 targeting drugs than PD-L1 ow.ly/5PPt30cIL6H

PD-L2 Adds Value to Immunotherapy Prediction in Head and Neck Cancers, Merck Study Finds

New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.

genomeweb.com
#Keytruda dominates #clinicaltrials #Immunotherapy PD-L1. nitter.gq/evaluatepharma/status/…
Evaluate Pharma (@evaluatepharma) profile pictureEvaluate Pharma@evaluatepharma12 Jun 2017
#ImmunoOncology combo trials triple since 2015 - 765 studies listed in 2017. New @EPVantage #PD1/ #PDL1 Combo report ow.ly/GdJ030cehmL
Image from Evaluate Pharma (@evaluatepharma)
Image from Evaluate Pharma (@evaluatepharma)
Emerging #liquidbiopsy concepts. Ready for clinical practice? Summarizes technologies and mutations. @BMCMedicine bit.ly/2sk2aRE
goo.gl/LTjEJS 'Tumor Agnostic' Cancer Drugs Seen Boosting Wider Genetic Tests
1
1
Geneuity retweeted
@gulleyj1 (@gulleyj1) profile picture
@gulleyj1@gulleyj12 Jun 2017
#ASCO17 One factor differentiating new PDL1 agents is ability to mediated ADCC. May be an important consideration for combination studies.
Image from @gulleyj1 (@gulleyj1)
4
64
11
66
1st time #FDA approves drug ( #keytruda ) based on a tumour’s biomarker (MSI-H or dMMR) regardless of tumour origin fda.gov/newsevents/newsroom/…
NCI ALMANAC Tool for Research on Cancer Drug Combinations cancer.gov/news-events/cance…

NCI ALMANAC Tool for Research on Cancer Drug Combinations

A Cancer Currents blog post on the NCI ALMANAC, a new resource that provides data showing how well pairs of FDA-approved cancer drugs performed in killing tumor cells from NCI-60 Human Tumor Cell...

cancer.gov
New Drug Repurposing e-learning from ecancer and ReDO. @ecancer ecancer.org/news/11632-new-d…
#Atezolizumab #PDL1 checkpoint inhibitor phase 3 study fails #bladdercancer trial. @EuroBiotechNews bit.ly/2pzufQ3
NIH and FDA Release Protocol Template for Phase 2 and 3 IND/IDE Clinical Trials grants.nih.gov/grants/guide/…
1
Comparison of methods; ctDNA #Biomarkers for Cancer Detection hold promise, clinical validation needed @ELS_Genetics bit.ly/2oTMeRv
Integrated pathology/molecular reports; Protocol review & biomarker selection for your next #clinicaltrial; Consult geneuity.com/experience/
Load more